Targeted Genetics resumed a gene therapy trial yesterday after a halt by the FDA due to the death of one of the participants. The therapy was aimed at alleviating arthritis by injecting patients with a virus genetically modified to encode an anti-inflammatory protein. A federal gene therapy committee will discuss the implications of this death at an NIH conference in Washington on Dec. 3.
http://www.iht.com/articles/ap/2007/11/26/america/NA-MED-US-Gene-Therapy.php
MC Masters
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment